Evidence map›Paper›PMID 41945876›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Hierarchical Targeting of TREM2

Fanglu Chen, Yucheng Xue, Xiao Ma, Liang Chen, Zhenxuan Shao, Hangxiang Sun, Haochen Mou, Fangqian Wang, Zilong Li, Yechao Shen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fanglu ChenMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Yucheng XueMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Xiao MaMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Liang ChenMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Zhenxuan ShaoMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Hangxiang SunMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Haochen MouMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Fangqian WangMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Zilong LiMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Yechao ShenMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Zhaoming YeMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Xiaohua YuMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.
Shengdong WangMusculoskeletal Tumor Center, Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China.ORCID https://orcid.org/0009-0007-2702-364X

Funding

5510 Project of the Second Affiliated Hospital of Zhejiang University 551005322022Central Guidance on Local Science and Technology Development Fund of Zhejiang Province 2024ZY01033Medical Science and Technology Project of Zhejiang Province 2023RC171National Natural Science Foundation of China 82372381Natural Science Foundation of Zhejiang Province LMS26H160005
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) bone metastasis is characterized by an immunosuppressive microenvironment dominated by triggering receptor expressed on myeloid cells 2 (TREM2)

Indexed as

Bone NeoplasmsMembrane GlycoproteinsMyeloid CellsOsteolysisReceptors, ImmunologicTriple Negative Breast NeoplasmsAnimalsFemaleHumansMiceTumor MicroenvironmentMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanimmunotherapymyeloid‐driven immunosuppressionosteoclastTREM2triple‐negative breast cancer bone metastasis

Identifiers

PMID41945876
PMCPMC13252654

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.